NeuroSense Therapeutics (NRSN) Earnings Analysis
NeuroSense Therapeutics (NRSN) next reports earnings on 2026-09-02, consensus EPS -0.195 USD. Last quarter (2026-04-06) it missed with EPS -0.235 USD vs -0.0708 USD est (-231.9%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -1.46.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does NRSN next report earnings?
| Next earnings date | 2026-09-02 |
|---|---|
| Consensus EPS estimate | -0.195 USD |
| Revenue estimate | 0.00B |
NRSN earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-06 | -0.235 USD | -0.0708 USD | -231.9% | Miss |
| 2025-12-17 | -0.11 USD | n/a | n/a | n/a |
| 2025-05-28 | -0.10925 USD | -0.10425 USD | -4.8% | Miss |
| 2025-04-07 | -0.06 USD | -0.11 USD | +45.5% | Beat |
| 2024-12-18 | -0.11 USD | -0.16 USD | +31.3% | Beat |
| 2024-09-30 | -0.02 USD | -0.2 USD | +90% | Beat |
Beat rate: 3/5 (60%) over reported quarters with consensus data.
NRSN valuation and analyst view
| Trailing P/E | -1.46 |
|---|---|
| Trailing EPS | -0.43525 USD |
| Price / book | -10.65 |
| Dividend yield | 0.00% |
| Market cap | 0.02B |
| Analyst consensus | Buy (1 buy / 1 hold / 0 sell) |
Related research pages
Frequently asked questions
When is NeuroSense Therapeutics (NRSN)'s next earnings date?
NeuroSense Therapeutics is next scheduled to report on 2026-09-02, with a consensus EPS estimate of -0.195 USD and revenue estimate of 0.00B.
Did NRSN beat earnings last quarter?
In its 2026-04-06 report, NRSN posted EPS of -0.235 USD versus a -0.0708 USD estimate — a miss of 231.9%.
What is NRSN's earnings track record?
Over the last 5 reported quarters with consensus data, NRSN beat estimates 3 times (60%).
What is NRSN's current P/E ratio and EPS?
NRSN trades at a trailing P/E of -1.46 on trailing EPS of -0.4352503912363067 USD.
What do analysts rate NRSN?
Analyst consensus is "Buy" across 2 ratings (0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell).